Investment
Features
FeesSafety
Academy
More
Pluang+

Compare Tractor Supply Co (TSCO) vs Vertex Pharmaceuticals Incorporated (VRTX) Price & Performance

Tractor Supply CoTrade
Vertex Pharmaceuticals IncorporatedTrade

Price performance (Past 24H)

Key statistics

Tractor Supply Co vs Vertex Pharmaceuticals Incorporated — how do they compare? Tractor Supply Co trades at $35.43 (market cap $18.05B), while Vertex Pharmaceuticals Incorporated trades at $528.01 (market cap $132.79B). The key difference: Vertex Pharmaceuticals Incorporated is far larger — about 7.4× Tractor Supply Co's market cap, and Tractor Supply Co pays a 2.77% dividend while Vertex Pharmaceuticals Incorporated pays none. Which is the better fit depends on your goals.

TSCOVRTX
Market Cap
$18.05B$132.79B
Sector
Consumer CyclicalHealth
52-Week High
$62.65$529.65
52-Week Low
$29.14$376.62
Enterprise Value
$24.36B$126.92B
Dividend Yield
2.77%

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

Tractor Supply Co

TSCO trades at $34.56, up 1.38% today, with a bullish technical signal from moving averages but overbought RSI readings. Recent earnings misses and a lowered 2026 outlook reflect cyclical headwinds, though the stock remains supported by a 48% buy rating from analysts and a $36.29 consensus price target. Cash flow from operations remains strong at $1.64B for 2025, but net cash flow was negative due to investments and financing activities.

The outlook is mixed: valuation reset and insider buying signal confidence, but weak discretionary demand and cost pressures pose near-term risks. Long-term opportunities exist from digital growth and pet initiatives, yet investors face volatility from earnings uncertainty and macroeconomic sensitivity.

Vertex Pharmaceuticals Incorporated

Vertex Pharmaceuticals (VRTX) trades at $496.07, up 2.49% on the day, with a bullish technical signal from moving averages and strong institutional support. The company reported Q2 2026 revenue of $3.3 billion, beating estimates, and raised its full-year sales outlook, driven by cystic fibrosis treatments and newer products like CASGEVY. Financials show robust profitability with a 35% net income margin and positive cash flow trends, though recent EPS results have been mixed.

Outlook remains positive with an 84% analyst buy rating and a $534.25 consensus price target, implying upside. Key risks include execution on new product launches and competitive pressures, but solid fundamentals and raised guidance support a constructive view for investors seeking growth in biopharma.

Returns comparison

Trailing returns across standard periods

Top news

Latest headlines on both assets

About Tractor Supply Co

Tractor Supply is the largest operator of retail farm and ranch stores in the United States. The company targets recreational farmers and ranchers and has little exposure to commercial and industrial farm operations. Currently, the company operates 2,016 of its namesake banners in 49 states and 178 Petsense stores. Stores are typically located in towns outside of urban areas and in rural communities. In fiscal 2021, revenue consisted primarily of livestock and pet (47%), hardware, tools, and truck (21%), and seasonal gift and toy (21%).

Read more on TSCO

About Vertex Pharmaceuticals Incorporated

Vertex Pharmaceuticals is a global biotechnology company that discovers and develops small-molecule drugs for the treatment of serious diseases. Its key drugs are Kalydeco, Orkambi, Symdeko, and Trikafta/Kaftrio for cystic fibrosis, where Vertex therapies remain the standard of care globally. In addition to its focus on cystic fibrosis, Vertex is diversifying its pipeline through gene-editing therapies such as CTX001 for beta-thalassemia and sickle-cell disease, small-molecule inhibitors targeting acute and chronic pain using non-opioid treatments, and small-molecule inhibitors of APOL1-mediated kidney diseases. Vertex is also investigating cell therapies to deliver a potential functional cure for type 1 diabetes.

Read more on VRTX